AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02035956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC MUTANOME, RBL001/RBL002
Description: Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
Study NCT00004474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Given on Day 0
Study NCT01107119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated care pathway
Description: communication and follow-up program for integrated care
Study NCT01107119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT04041206 — intervention group
Intervention type: DEVICE
Intervention: Laser doppler
Description: Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian
Study NCT02564861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
Study NCT02564861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching DS-1971a suspension
Study NCT01012921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: barrier membrane
Description: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Study NCT01012921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: barrier membrane
Description: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Study NCT01012921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MembraGel
Description: Device application at surgery
Study NCT01012921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide® membrane
Description: Device application at surgery
Study NCT01666639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medical Rehabilitation plus behavioral exercise therapy
Description: The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity.
Study NCT01666639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Behavioral Medical Rehabilitation
Description: The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each.
Study NCT03610867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SAD)
Description: Each subject will receive the sample once by oral administration.
Study NCT03610867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MAD)
Description: Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
Study NCT00836459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Booster
Description: Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
Study NCT00836459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Booster
Description: Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
Study NCT01256281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
Study NCT00974285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 1
Description: Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT00974285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT01573637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
Study NCT01329406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 1 tablet (100mg) by mouth twice daily for 28 days
Study NCT01329406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet by mouth twice daily for 28 days
Study NCT03398668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relievion device- Treatment stimulation
Description: 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
Study NCT03398668 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relievion Device- Sham stimulation
Description: 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
Study NCT01630304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WelTel SMS service
Description: Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician.
Study NCT01603108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
Study NCT01603108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
Study NCT02751710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body FDG PET-CT alone
Description: FDG PET-CT imaging
Study NCT01863225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg daily, 28-42 days
Study NCT01863225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg daily, 28-42 days
Study NCT01863225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg daily, 28-42 days
Study NCT01573637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactosa (placebo arm)
Description: Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
Study NCT03515941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 by IV (Arm 1)
Study NCT03515941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
Study NCT03515941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by IV (Arm 1 \& Arm 2)
Study NCT03540524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 dose regimen A
Description: GLPG2451 oral suspension, daily.
Study NCT03515941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
Study NCT01863225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg daily, 28-42 days
Study NCT01394679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
Description: One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
Study NCT01394679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18 F FDG followed by PET/CT imaging
Description: Single injection of 18 F FDG range of 10-20 mCi
Study NCT01375985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-7100
Description: Single intravenous administration
Study NCT03540524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 dose regimen B
Description: GLPG2451 oral suspension, daily.
Study NCT03515941 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 45 Gy in 1.8 Gy/fraction
Study NCT01375985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single intravenous administration
Study NCT01638806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group I: Primary PCI
Description: Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT02648451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES ROME
Description: AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
Study NCT02606760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3073
Study NCT03540524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222
Description: GLPG2222 tablet for oral use, daily.
Study NCT02606760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of P-3073
Study NCT04143243 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT on Life
Description: 1 day group workshop of ACT plus ERS
Study NCT04143243 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education, Resources, and Support
Description: 1 day group workshop of Education, Resources, and Support
Study NCT04218162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50mg
Description: Lasmiditan 50mg
Study NCT04218162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100mg
Description: Lasmiditan 100mg
Study NCT04218162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03480789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
Study NCT03900897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL SYNCHRONY PIN Cochlear Implant
Description: Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
Study NCT05237414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 20 minutes of 2.0 mA direct current applied over the right DLPFC
Study NCT05237414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: 15 seconds of 2.0 mA direct current applied over the right DLPFC
Study NCT03480789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: wearing the eye patch from 22:00 to 6:00 of the next day
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT01689350 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype Detection
Description: To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
Study NCT04139681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Vogels Sore Throat lozenges
Description: 5 times 1 A. Vogels sore throat lozenges daily for 4 days
Study NCT01537081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex
Description: Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
Study NCT01537081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-release Guaifenesin
Description: Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
Study NCT03630120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study NCT01460420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bz (Bortezomib)
Description: Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
Study NCT01460420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Len (lenalidomide)
Description: Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified.
Study NCT02689401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study NCT02689401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3T scanner
Study NCT01096121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: * during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day
Study NCT01096121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose
Study NCT01169610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
Study NCT02059057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LVRC System
Study NCT00825045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
Study NCT00768807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Description: Patients treated by CPAP for 06 months
Study NCT00768807 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Description: Patients treated by CPAP for 06 months
Study NCT03437720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection